Langerhans cell histiocytosis in children under 2 years of age

Medical and Pediatric Oncology
R Rivera-LunaG Martínez-Guerra

Abstract

This is a retrospective study of 55 children under the age of 2 years diagnosed with Langerhans cell histiocytosis (LCH). They were classified according to age and organ function and dysfunction following Lahey's criteria. The studied population was divided into four groups by age of diagnosis (0-6, 7-12, 13-18, and 19-24 months). Statistical analysis showed no significant difference in outcome between age groups, although the population under 6 months had a 81.3% fatality rate. The presence of organ dysfunction was a major cause of death in all age groups, being statistically significant in outcome (P > 0.005) compared with patients without organ dysfunction. The presence of thrombocytopenia and/or respiratory dysfunction was also highly associated with a fatal outcome. In the surviving population, no second malignancies have been reported. The late secondary effects of therapy include endocrine, orofacial, and osseous pathologies.

References

Sep 1, 1978·American Journal of Clinical Pathology·K Daneshbod, J M Kissane
Aug 1, 1975·The Journal of Pediatrics·E Lahey
Aug 1, 1975·The Journal of Pediatrics·M E Lahey
Jan 1, 1989·Medical and Pediatric Oncology·V BroadbentE Yeomans
Oct 26, 1989·The New England Journal of Medicine·D B DungerJ Pritchard
Aug 1, 1988·Pediatric Dermatology·R Rivera-LunaE Lopez-Corella
Jan 1, 1986·Medical and Pediatric Oncology·D H BerryR Marcus
Mar 19, 1987·The New England Journal of Medicine·D M Komp
Jul 1, 1985·Archives of Disease in Childhood·V Broadbent, J Pritchard
Jan 1, 1985·Pediatric Pathology·C Nezelof, S Barbey
Jan 1, 1981·The American Journal of Pediatric Hematology/oncology·B E Favara
Oct 1, 1983·Pediatric Dermatology·J M Lipton
Jan 15, 1981·The New England Journal of Medicine·M E OsbandR Parkman
Jan 1, 1983·Medical and Pediatric Oncology·M Matus-RidleyA T Meadows
Feb 1, 1980·The Journal of Pediatrics·K A StarlingR C Trueworthy
Jan 1, 1980·Medical and Pediatric Oncology·D M KompS L George
Sep 1, 1981·Medicine·J S GreenbergerJ R Cassady
Jan 1, 1981·The American Journal of Pediatric Hematology/oncology·D M Komp
Jan 1, 1981·The American Journal of Pediatric Hematology/oncology·K A Starling
Jan 1, 1981·The American Journal of Pediatric Hematology/oncology·W H Bunch
Jan 1, 1995·Critical Reviews in Oncology/hematology·R M Egeler, M E Nesbit
Jul 21, 1994·The New England Journal of Medicine·C L WillmanD G Gilliland
Jan 1, 1994·Medical and Pediatric Oncology·H GadnerS Ladisch
Jan 1, 1994·Medical and Pediatric Oncology·R M EgelerM E Nesbit
Jan 1, 1993·Medical and Pediatric Oncology·M AricòR M Egeler

❮ Previous
Next ❯

Citations

Mar 22, 2001·Medical and Pediatric Oncology·C BernstrandJ I Henter
Nov 15, 2008·International Journal of Dermatology·Klara MosterdMaurice A M van Steensel
Dec 15, 2005·Advances in Dermatology·Kristen E HollandBeth A Drolet
Jul 6, 2014·Scottish Medical Journal·Allison MartinRobert Carachi
Mar 17, 2005·Pediatric Blood & Cancer·M MinkovH Gadner
Dec 11, 1996·International Journal of Cancer. Journal International Du Cancer·E Kramárová, C A Stiller
Oct 12, 2000·Medical and Pediatric Oncology·G SuricoH Gadner
Oct 3, 1999·Pediatric Hematology and Oncology·J BraierJ Goldberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.